Cardiol Therapeutics (TSE:CRDL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, testing CardiolRx™ in treating acute myocarditis, a serious inflammatory heart condition. The trial’s results, expected next year, could provide significant insights into the drug’s impact on heart recovery, with no current FDA-approved treatments for this condition. The company sees this as an opportunity to develop a new therapy that could benefit from orphan drug status, offering potential market exclusivity and other incentives.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.